Retatrutide Dosage Protocol (5 mg Vial)

Straightforward 12-week and 24-week planning for a 5 mg vial at 5 mg/mL.

• Retatrutide vials (5 mg each):
  • Phase 2, 12 weeks: Minimum 12 vials (56 mg required).
  • Phase 2, 24 weeks: Minimum 40 vials (200 mg required).
  • Phase 3, 12 weeks: Minimum 10 vials (48 mg required).
  • Phase 3, 24 weeks: Minimum 36 vials (180 mg required).
• U-100 insulin syringes (1 mL capacity):
  • Phase 2, 12 weeks: 16 new syringes.
  • Phase 2, 24 weeks: 52 new syringes.
  • Phase 3, 12 weeks: 16 new syringes.
  • Phase 3, 24 weeks: 48 new syringes.
• Bacteriostatic water (10 mL bottles):
  • Phase 2, 12 weeks: 2 bottles by volume (12 mL required).
  • Phase 2, 24 weeks: 4 bottles by volume (40 mL required).
  • Phase 3, 12 weeks: 1 bottle by volume (10 mL required).
  • Phase 3, 24 weeks: 4 bottles by volume (36 mL required).
• Alcohol swabs:
  • Phase 2, 12 weeks: 32 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 2, 24 weeks: 104 swabs minimum; 2 boxes of 100 covers the calculation.
  • Phase 3, 12 weeks: 32 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 24 weeks: 96 swabs minimum; 1 box of 100 covers the calculation.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Retatrutide 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 1 mL of bacteriostatic water to produce 5 mg/mL.
• Research frequency: Once weekly by subcutaneous administration in the cited human trials.^[1][3][5]
• Weekly research range: The cited programs evaluated target amounts through 12 mg weekly.^[1][2][3]
• Easy measuring: 1 U-100 unit = 0.01 mL = 50 mcg.
• Vial size: The 5 mg label is total nominal vial content, not a weekly amount. Weekly research amounts above 5 mg require enough vials to supply the total nominal mass.
• Vial coverage: At the 2 mg research stage, one vial supplies 2 full weekly amounts with 1 mg remaining. At the 12 mg research stage, the 12 mg amount requires 3 separate 5 mg vials by nominal mass. These are mass calculations, not vial storage or discard periods.

• Research route and frequency: The cited clinical trials used once-weekly subcutaneous administration.^[1][2][3][5]
• Studied target doses: Phase 2 included 1 mg, 4 mg, 8 mg, and 12 mg groups; phase 3 programs evaluated 4 mg, 9 mg, and 12 mg targets.^[1][2][3]
• 5 mg vial concentration: 5 mg divided by 1 mL equals 5 mg/mL.
• U-100 conversion: 1 unit equals 0.01 mL or 50 mcg at this concentration.
• Evidence boundary: Trial schedules describe investigated products, populations, and monitoring plans. They are not individualized dosing instructions.^[1][3][5][6]

• Phase 2 lower-start 12 mg arm: 2 mg, 4 mg, 8 mg, then 12 mg in four-week stages.^[1][10]
• Phase 3 12 mg target: 2 mg, 4 mg, 6 mg, 9 mg, then 12 mg in four-week stages.^[2][3]
• Other target groups: The trials included lower assigned targets; not every participant escalated to 12 mg.^[1][2][3][5]
• Measurement: The primary chart keeps peptide mass, U-100 units, mL, and once-weekly frequency together.
• Strength consistency: Vial size changes concentration, vial yield, and supply totals; it does not change the assigned research amount.

• Before reconstitution: Keep the lyophilized vial dry, protected from light, and stored according to the exact product documentation.
• After reconstitution: Refrigerate only as the supplied formulation and diluent instructions permit.
• Label the vial: Record the 5 mg/mL concentration, reconstitution date, storage conditions, and documented discard date.
• Handling: Gently swirl or roll rather than shake the vial, and avoid unnecessary agitation or repeated freeze-thaw cycles because peptide stability is formulation-dependent.^[16]

For this 5mg vial, adding 1 mL of bacteriostatic water determines the final concentration: 5 mg/mL. The conversion below explains how the reconstituted peptide maps to U-100 insulin-syringe markings and how many nominal vials each research amount requires.

• 2 mg: 0.40 mL or 40 units. One 5mg vial contains two complete 2 mg amounts with 1 mg remaining.
• 4 mg: 0.80 mL or 80 units. One vial contains one complete 4 mg amount with 1 mg remaining.
• 6 mg: 1.20 mL or 120 units. The amount exceeds one vial and one 1 mL syringe, so the supply calculation requires two vials and two syringes.
• 8 mg: 1.60 mL or 160 units. The calculation requires two 5mg vials and two syringes.
• 9 mg: 1.80 mL or 180 units. The calculation requires two vials and two syringes.
• 12 mg: 2.40 mL or 240 units. The calculation requires three 5mg vials and three syringes. Vial-yield figures are arithmetic, not storage or discard periods.

This step-by-step reconstitution protocol uses the page's stated 1 mL volume. Reconstitute Retatrutide only under the governing laboratory procedure and the exact product documentation; Retatrutide is an investigational peptide.^{[6][13][14][15]}

• Prepare: Wash hands, establish a clean work area, gather a sterile syringe and alcohol swabs, and clean the tops of both vials. Allow the surfaces to dry.^[13][14][15]
• Add bacteriostatic water: Draw 1 mL, insert the needle into the Retatrutide vial at an angle, and direct the liquid slowly down the wall of the vial rather than directly onto the powder cake.
• Dissolve gently: Gently swirl or roll the vial. Do not shake the vial. Wait until the lyophilized powder has dissolved and inspect the solution according to the product documentation.
• Label and store: Label the vial with 5 mg/mL, the reconstitution date, and the documented storage and discard information. Refrigerate only as the exact formulation permits.
• Check the arithmetic: At 5 mg/mL, 1 U-100 unit is 50 mcg, 40 units is 2 mg, and 80 units is 4 mg. Recompute every measurement if the water volume changes.
• Technique check: Before beginning Retatrutide reconstitution, inspect the lyophilized peptide container and verify the documented BAC-water volume. To reconstitute Retatrutide, use sterile technique; add the bacteriostatic water slowly against the glass wall, then swirl gently. Continue gentle swirling only as needed, avoid air bubbles, and inspect the reconstituted peptide for visible particles. Refrigerate the prepared solution only as the exact product documentation permits. This peptide reconstitution workflow explains measurement, not a clinical dose.^{[13][14][15][16]}

Retatrutide dosing in published studies was organized by randomized target group and gradual escalation. The trial protocol determines the research schedule; the amount printed on a peptide vial does not.^[1][2][3][5]

• Phase 2 obesity trial: Participants were assigned to placebo or Retatrutide target groups of 1 mg, 4 mg, 8 mg, or 12 mg once weekly. Higher target groups used different starting and escalation approaches.^[1][10]
• Phase 2 type 2 diabetes trial: Multiple assigned Retatrutide doses and an active comparator were evaluated in a different population and endpoint framework.^[5][12]
• TRIUMPH phase 3 design: Once-weekly subcutaneous target doses were reached through planned four-week escalation stages.^[2]
• TRANSCEND-T2D-1: Adults with type 2 diabetes were evaluated in 4 mg, 9 mg, and 12 mg target groups.^[3]
• Protocol interpretation: The registered phase 2 study defines its tested population, product, and monitoring plan; it does not validate a separately manufactured research vial or a self-directed schedule.^[6]

Retatrutide is an investigational single-molecule agonist designed to activate GIP, GLP-1, and glucagon receptors. This triple-receptor profile is being studied for metabolic disease rather than treated as proof of a safe dose for an individual.^[4][7][8]

• GIP and GLP-1: Receptor activity contributes to glucose-dependent insulin signaling, appetite regulation, and nutrient-response pathways.
• Glucagon receptor: Agonist activity adds a distinct energy-expenditure and hepatic-signaling component to the research profile.
• Translational evidence: Preclinical and early clinical work describes receptor balance and the pharmacokinetic properties that supported once-weekly clinical-trial dosing.^[4]
• Evidence limits: Reviews of multi-receptor agonists explain the scientific rationale but do not establish an approved Retatrutide dosage.^[7][8]

Clinical findings must be interpreted by target dose, population, follow-up period, and analysis plan. Results cannot be transferred automatically to a different formulation or research setting.

• Body-weight outcomes: The 48-week phase 2 obesity trial reported dose-related mean changes, with the largest average reduction in the 12 mg target group.^[1]
• Glycemic outcomes: The phase 2 type 2 diabetes trial reported changes in glycated hemoglobin and body weight across evaluated groups.^[5]
• Phase 3 evidence: TRANSCEND-T2D-1 reported glycemic and body-weight findings at 40 weeks in adults with type 2 diabetes.^[3]
• Cardiometabolic context: Cardiovascular and metabolic measures were secondary or exploratory outcomes and require population-specific interpretation.^[1][3][5][9]
• Liver-fat substudy: A randomized phase 2a trial evaluated liver-fat change in participants with metabolic dysfunction-associated steatotic liver disease; it does not convert this 5mg vial calculation into a liver-treatment protocol.^[11]

Safety findings belong to the investigated products, monitored participants, and controlled escalation plans. A reconstitution chart explains concentration and syringe measurements; it does not reproduce clinical oversight.

• Commonly reported events: Gastrointestinal events including nausea, diarrhea, vomiting, and constipation were among those reported most often.^{[1][3][5][12]}
• Escalation period: Events were more frequent during dose escalation and were generally mild to moderate in the phase 2 obesity trial.^[1]
• Starting amount: A 2 mg start improved gastrointestinal tolerability compared with a 4 mg start in the phase 2 obesity study.^[1]
• Heart rate: Dose-dependent increases were observed in phase 2 and declined after peaking during follow-up.^[1]
• Research boundary: Trial-design papers and registries describe eligibility, comparators, and monitoring that are not reproduced by vial math.^[2][6]
• Product equivalence: Retatrutide evidence comes from monitored trials. A separate Retatrutide vial calculation does not establish peptide quality, stability, or equivalence to the investigated product.^{[1][2][3][5][6]}

These frequently asked questions clarify 5mg Retatrutide reconstitution, vial yield, and the clinical-trial context without turning research evidence into individualized medical advice.

• How much bacteriostatic water does this chart use? It uses 1 mL for a final concentration of 5 mg/mL. A different BAC-water volume requires a complete recalculation.
• How many U-100 units equal 1 mg? At 5 mg/mL, 1 mg equals 0.20 mL or 20 units; 2 mg equals 40 units; and 4 mg equals 80 units.
• Does a 5mg vial change the Retatrutide dose? No. It changes concentration, syringe volume, vial yield, and supply counts. Clinical-trial target doses came from the study protocol.^[1][2][3][5]
• Did every participant escalate to 12 mg? No. The trials included several assigned target groups.^[1][2][3][5]
• Why do amounts above 5 mg require multiple vials? They exceed the nominal peptide mass in one 5mg vial. The chart therefore counts enough containers and 1 mL syringes to supply the total mass and volume.
• How should administration be documented? Follow the governing protocol, use a new sterile syringe for each injection and vial entry, clean the stopper and selected site, rotate sites, record mass, units, mL, date, and site, and place used sharps in an appropriate container.^[13][14][15]

This page explains how to reconstitute a 5 mg Retatrutide vial using the stated 1 mL example and translates published human-research schedules into concentration, U-100 units, mL, vial yield, and supply calculations. It does not establish an approved product, a recommended dose, or individualized medical advice. Retatrutide remains investigational.

• 1
  New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trial

  View Source
• 2
  Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalation

  View Source
• 3
  The Lancet (2026): TRANSCEND-T2D-1 randomized phase 3 retatrutide trial

  View Source
• 4
  Cell Metabolism (2022): Discovery and translational pharmacology of LY3437943

  View Source
• 5
  The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trial

  View Source
• 6
  ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760

  View Source
• 7
  Current Obesity Reports (2025): Triple agonism-based therapies for obesity

  View Source
• 8
  Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic disease

  View Source
• 9
  Diabetes Care (2024): Incretin-based therapies and cardiovascular considerations

  View Source
• 10
  New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trial

  View Source
• 11
  Nature Medicine (2024): Retatrutide for metabolic dysfunction-associated steatotic liver disease: randomized phase 2a trial

  View Source
• 12
  The Lancet (2023): Supplementary data for the phase 2 diabetes trial

  View Source
• 13
  CDC: Subcutaneous administration guidance

  View Source
• 14
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 15
  NCBI Bookshelf: Best practices for injections and related procedures

  View Source
• 16
  Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cycles

  View Source

Compare the other Retatrutide vial sizes and practical measurement guides.